[Headlines Only] [Top Stories Only]
Categories
· Health/Science
· Cessation
· Zyban
· Genes

CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial 

Volume 62, Issue 6, pages 635-641 (15 September 2007)
Jump to full article: Journal of Substance Abuse, 2007-09-13

Intro:

Background

CYP2B6 is the primary enzyme involved in bupropion metabolism. Genetic polymorphisms in CYP2B6, such as CYP2B6*6, can alter bupropion metabolism and may affect bupropion treatment outcome.

Conclusions

These data suggest that smokers with the CYP2B6*6 genotype have a higher liability to relapse on placebo and that they may be good candidates for bupropion treatment for smoking cessation.

Jump to full article »